Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact
Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development…
Diversify With These Health ETFs
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in…
FDA approves high-dose Wegovy shots
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help…
2 Top AI Healthcare Stocks to Buy and Hold
Many of the top companies successfully cashing in on artificial intelligence (AI) are in the technology sector. However,…
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
March 2 (Reuters) – Eli Lilly CFO ‌Lucas Montarce said ‌on Monday it is ​preparing to launch its…
The Best Healthcare Stock to Invest $1,000 in Right Now
When you think “top-performing pharma stock,” Eli Lilly may first come to mind. Yet while Lilly’s shares have…
1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…
NHS must keep medicine rebate down or lose investment
Wednesday 18 February 2026 2:27 pm  |  Updated: Wednesday 18 February 2026 3:10 pm Share Facebook Share on Facebook…
JPMorgan builds $2.93 billion stake in health care stock
JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the…
New peptide drugs on the horizon with PepLib–Lilly collab
New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity. Think…
What’s the Better Long-Term Investment?
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are rivals in the GLP-1 drug market and are…
The most controversial Super Bowl ad of 2025 is back for more
Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…